1-Year Safety and Effectiveness of a Next-Generation Dual-Seal Left Atrial Appendage Occluder
JACC: Cardiovascular Interventions · 2026-11
DOI: 10.1016/j.jcin.2026.10.023 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2026-11. Verfasst von Dhanunjaya Lakkireddy und 22 weiteren Autor:innen. Beteiligte Einrichtung: Kansas City Heart Rhythm Institute and Research Foundation, Overland Park, Kansas, USA. Electronic address: dhanunjaya.lakkireddy@hcahealthcare.com. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbott Laboratories.
Abstract (Originalsprache)
BACKGROUND: Left atrial appendage occlusion (LAAO) is a stroke prevention alternative for patients with atrial fibrillation (AF) intolerant to long-term oral anticoagulation (OAC). The next-generation dual-seal device was designed to improve operator ease of use while maintaining effective LAAO of the predicate device. OBJECTIVES: The purpose of this analysis was to evaluate the safety and effectiveness of a next-generation device through 1 year. METHODS: VERITAS is a single-arm, prospective, global, multicenter study. Patients with nonvalvular AF with an increased thromboembolism risk seeking a nonpharmacologic alternative to OAC were enrolled. One-year descriptive endpoints are provided, including mortality, neurological events, major bleeding, and device-related complications. One-year cardiac imaging was assessed for peridevice leak and device-related thrombus (DRT). RESULTS: Complete left atrial appendage (LAA) closure (0 mm leak) was observed in 91.1% (95% CI: 87.9%-93.7%) of patients by either transesophageal echocardiography (TEE) or cardiac computed tomography and 96.3% (95% CI: 93.2%-98.2%) by TEE alone. The cumulative DRT rate was 3.3% (95% CI: 2.0%-5.3%) with only 0.4% (95% CI: 0.1%-1.5%) deemed clinically relevant. One-year key clinical outcome rates are as follows: all-cause mortality: 3.9% (95% CI: 2.4%-6.3%); cardiovascular mortality: 1.9% (95% CI: 0.9%-3.8%); major bleeding: 6.6% (95% CI: 4.5%-9.2%); ischemic stroke or systemic embolism: 1.8% (95% CI: 0.8%-3.3%); pericardial effusion requiring intervention: 0.9% (95% CI: 0.3%-2.1%). No (0%) device embolization occurred. Median follow-up was 365 days (IQR: 349-380 days). CONCLUSIONS: The VERITAS study results support the 1-year safety and effectiveness of the next-generation device. (Abbott Medical-VERITAS Study; NCT06707688).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kansas City Heart Rhythm Institute and Research Foundation, Overland Park, Kansas, USA. Electronic address: dhanunjaya.lakkireddy@hcahealthcare.com.
- Arizona Heart Arrhythmia Associates, Phoenix, Arizona, USA.
- Mayo Clinic, Rochester, Minnesota, USA.
- Hospital Clinic of Barcelona, Barcelona, Spain.
- Heart Rhythm Associates, Woodlands, Texas, USA.
- CHI Creighton University School of Medicine - Bergan Mercy Hospital, Omaha, Nebraska, USA.
Förderung
- Abbott Laboratories
Zitieren
APA
Lakkireddy, D., Makkar, A., Alkhouli, M., Freixa, X., Manoukian, G., Agarwal, H., Abuissa, H., Awad, K., Cuoco, F., Dohadwala, M., Ellis, C. R., Shah, D., De Backer, O., Chinitz, L., Nielsen-Kudsk, J. E., Horton, R. P., Schmidt, B., Natale, A., Reddy, V. Y., …, & VERITAS Investigators (2026). 1-Year Safety and Effectiveness of a Next-Generation Dual-Seal Left Atrial Appendage Occluder. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2026.10.023
Vancouver
Lakkireddy D, Makkar A, Alkhouli M, Freixa X, Manoukian G, Agarwal H, et al. 1-Year Safety and Effectiveness of a Next-Generation Dual-Seal Left Atrial Appendage Occluder. JACC: Cardiovascular Interventions. 2026. doi:10.1016/j.jcin.2026.10.023
BibTeX
@article{Lakkireddy2026,
author = {Lakkireddy, Dhanunjaya and Makkar, Akash and Alkhouli, Mohamad and Freixa, Xavier and Manoukian, George and Agarwal, Himanshu and Abuissa, Hussam and Awad, Khaled and Cuoco, Frank and Dohadwala, Mustafa and Ellis, Christopher R and Shah, Dipak and De Backer, Ole and Chinitz, Larry and Nielsen-Kudsk, Jens Erik and Horton, Rodney P and Schmidt, Boris and Natale, Andrea and Reddy, Vivek Y and Sabir, Sajjad A and Weiler, Courtney and Nair, Devi and VERITAS Investigators, VERITAS Investigators},
title = {1-Year Safety and Effectiveness of a Next-Generation Dual-Seal Left Atrial Appendage Occluder},
journal = {JACC: Cardiovascular Interventions},
year = {2026},
doi = {10.1016/j.jcin.2026.10.023}
}
EUVIMED